PCSK9 and hyperlipidemia: Although data from various clinical trials firmly show an appreciable mitigating effect of the PCSK9 inhibitor evolocumab on hyperlipidemia in T2DM patients [32], there are still some concerns regarding the correlation between PCSK9 inhibitors and DM complications [33–36].